Larimar Therapeutics Files 8-K

Ticker: LRMR · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateNov 18, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, routine-filing, corporate-reporting

Related Tickers: LRMR

TL;DR

Larimar Therapeutics (LRMR) filed a routine 8-K on Nov 18, 2024. No major news.

AI Summary

Larimar Therapeutics, Inc. filed an 8-K on November 18, 2024, reporting other events and financial statements. The company, formerly known as Zafgen, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations industry. The filing does not disclose specific financial figures or significant events beyond its routine reporting nature.

Why It Matters

This 8-K filing indicates routine corporate reporting by Larimar Therapeutics, Inc. to the SEC, providing updates on company events and financial statements.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain any new material information that would significantly alter the company's risk profile.

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • Zafgen, Inc. (company) — Former company name
  • November 18, 2024 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • 203857670 (id) — IRS Number

FAQ

What is the primary purpose of this 8-K filing for Larimar Therapeutics, Inc.?

This 8-K filing is for reporting 'Other Events' and 'Financial Statements and Exhibits' as of November 18, 2024.

When was Larimar Therapeutics, Inc. formerly known as?

Larimar Therapeutics, Inc. was formerly known as Zafgen, Inc., with name changes noted on March 1, 2010, and September 6, 2006.

What is the principal executive office address for Larimar Therapeutics, Inc.?

The principal executive offices are located at Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004.

What is the SEC file number for Larimar Therapeutics, Inc.?

The SEC file number for Larimar Therapeutics, Inc. is 001-36510.

What is the IRS Employer Identification Number for Larimar Therapeutics, Inc.?

The IRS Employer Identification Number for Larimar Therapeutics, Inc. is 20-3857670.

Filing Stats: 463 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-11-18 07:02:24

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

01 Other Events

Item 8.01 Other Events. On November 18, 2024, Larimar Therapeutics, Inc. (the " Company ") posted on its website a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Larimar Therapeutics, Inc. Corporate Presentation, dated November 18, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: November 18, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.